(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Toxic Encephalopathy
Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00516503CT.gov Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer | — | Completed | — | — | — |
NCT00471445CT.gov Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Toxic Encephalopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone (this asset) | Alliance for Clinical Trials in Oncology | P3 | BB · 66 |
| Eribulin Monomethanesulfonate | Oncologia Medica dell'Ospedale Fatebenefratelli | P4 | BB |
| Procarbazine | Radiation Therapy Oncology Group | P2 | BB |
| Amitriptyline | Alliance for Clinical Trials in Oncology | P3 | BB |
| Carboplatin | Alliance for Clinical Trials in Oncology | P3 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P3 | BB |
| Amifostine | M.D. Anderson Cancer Center | P3 | BB |
| Methotrexate | Radiation Therapy Oncology Group | P2 | BB |
| (+)-Vincristine | Radiation Therapy Oncology Group | P3 | BB |
+38 more in the Toxic Encephalopathy cohort
Other indications for (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Traumatic Stress Disorder | — | P4 | BBB · 74 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone in Toxic Encephalopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/2-o-chlorophenyl-2-methylaminocyclohexanone-toxic-encephalopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →